Letter from the CEO

Letter from the CEO

With the first month of 2023 already behind us, it is time for me to reach out and wish you and your families a very good year, abundant with happiness, success, and positive experiences. We at ADL Biopharma are excited about the opportunities and adventures this new...
Capital increase strengthens ADL’s position

Capital increase strengthens ADL’s position

ADL BioPharma increases capital by EUR 24 million, which is 100% subscribed by Kartesia as the sole shareholder, by converting an equivalent amount of all its old loans in the company. In this way, ADL significantly reduces its debt ratios and financial interest...
Privacy overview

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team to understand which sections of the website you find most interesting and useful.

More information in the Privacy policy and Cookies policy.